Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | GSK2126458 |
Trade Name | |
Synonyms | GSK458|Omipalisib |
Drug Descriptions |
Omipalisib (GSK2126458) is a dual pan-PI3K and mTOR inhibitor, which blocks PI3K/AKT signaling to prevent cell proliferation (PMID: 24900173, PMID: 32382996). |
DrugClasses | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 |
CAS Registry Number | 1086062-66-9 |
NCIT ID | C88270 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Dabrafenib + GSK2126458 | Dabrafenib GSK2126458 | 6 | 0 |
Dasatinib + GSK2126458 | Dasatinib GSK2126458 | 0 | 0 |
GSK2126458 | GSK2126458 | 9 | 0 |
GSK2126458 + Lapatinib | GSK2126458 Lapatinib | 0 | 0 |
GSK2126458 + RXDX-105 | GSK2126458 RXDX-105 | 1 | 0 |
GSK2126458 + Trametinib | GSK2126458 Trametinib | 7 | 0 |